Replies to post #282891 on Avid Bioservices Inc (CDMO)

[jakedogman1]

he probably scored when bms bought inhibitex for $2.5 bil so he knows how the game is played

http://www.wsj.com/articles/SB10001424052970203471004577147543747719460

and pphm has made the pivot to manufacturing.... if the ip pans out, hopefully the ip is bought out (it begs for capable hands and resources)...

he was basically babysitting someone else's tech and probably not in the position to score big at pphm like the new opportunity provides... and i'm sure he has upside in pphm should they succeed...

on another note if you look at the heat, lattuck and pelican connections, the common theme is a very strong bod.... the former noble analyst is on the bod..

Dr. Jasuja has been involved with Pelican’s progress since 2013. Until recently, Dr. Jasuja was Managing Director, Biotechnology Research at Noble Life Science Partners (NLSP), a merchant and investment bank. At NLSP, Dr. Jasuja was instrumental in building a fundamentally driven life sciences research effort. Prior to NLSP, he was Vice President, Corporate Development, at Idera Pharmaceuticals, focused on developing toll-like receptor based immune-modulators. At Idera, his role included business development, alliance management, pipeline strategy, technology communication for out-licensing efforts. He contributed to the development strategy of Idera’s novel immune modulator (a toll-like receptor 7/9 antagonist) for autoimmune & inflammatory disease. Previously Dr. Jasuja held progressively senior positions in the biotechnology capital markets at Techvest, Rodman & Renshaw, and MDB Capital Group. He brings more than 20 years’ experience in the biotechnology field encompassing corporate/business development, technology due-diligence, equity research and academic research. He obtained his B.Sc. in Microbiology & Biochemistry from the University of Bombay (India), and his M.S. in Microbiology from the University of Montana, Missoula, where he studied the role of bacterial cell wall immune-modulators on arachidonic acid metabolism and inflammatory pathways in macrophages. Dr. Jasuja received his Ph.D. in Immunology from Tufts University School of Medicine, Boston, where he explored aspects of T cell activation and the subsequent regulation of adhesion receptors in the immune response. He conducted doctoral and post-doctoral research at Harvard Medical School, Boston, in the Dept. of Hematology & Oncology at Beth Israel Deaconess Medical Center.

the pphm bod couldn't come up with two sentences of experience... i would trade all three clowns for just jusuja...

absolute shame of what they have done...

http://www.pelicantherapeutics.com/aboutus.php

[JJ1223]

"I would like to welcome Dr. Hutchins to the Heat team," commented Jeff Wolf, Heat's Chief Executive Officer. "He brings a tremendous amount of industry experience, including preclinical research, clinical development and manufacturing. His expertise aligns with Heat's current pipeline and priorities, and positions us strongly as we move into 2017."

I thought nobody at Peregrine had any industry experience!

[asmarterwookie]

IAT...It would seem reasonable to administer BAVI first here just as in other IO products. Get the correct immuno cells in in the correct area then....

I still say Transcelerate should buy the APP so all can benefit.

Transcelerate would have to add a mission to their mission statement.
Never happen....Oops..A definitive statement.

Thanks IAT

wook